Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.69 |
| ▸ | RET | P07949 | 7/20 | 0.69 |
| ▸ | KIF5B | P33176 | 6/20 | 0.69 |
| ▸ | EGFR | P00533 | 8/20 | 0.67 |
| ▸ | FBP1 | P09467 | 2/20 | 0.67 |
| ▸ | GAK | O14976 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | ILK | Q13418 | 1/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.57 |
| ▸ | FLT1 | P17948 | 3/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1657704 | 0.89 | FBP1 (0.68) | KDRRETKIF5BEGFRFBP1 | |
| SCHEMBL1507598 | 0.88 | EGFR (0.70) | KDRRETKIF5BEGFRFBP1 | |
| Hydrochloric Acid SCHEMBL1507438 | 0.87 | EGFR (0.70) | KDRRETKIF5BEGFRFBP1 | |
| SCHEMBL27532830 | 0.86 | KDR (0.67) | KDRRETKIF5BEGFRMAPK14 | |
| Hydrochloric Acid SCHEMBL1507638 | 0.85 | KDR (0.65) | KDRRETKIF5BEGFRMAPK14 | |
| SCHEMBL27386749 | 0.84 | EGFR (0.62) | KDRRETKIF5BEGFRFBP1 | |
| SCHEMBL1507572 | 0.83 | EGFR (0.79) | KDRRETEGFRFBP1GAK | |
| SCHEMBL18158909 | 0.82 | RET (1.00) | KDRRETKIF5BEGFRGAK | |
| SCHEMBL6793966 | 0.82 | KDR (0.74) | KDRRETKIF5BEGFRMAPK14 | |
| SCHEMBL12200787 | 0.80 | RET (0.74) | KDRRETKIF5BEGFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2016-10-20 | — | — | US | claimed |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | claimed |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2015-02-26 | — | — | US | claimed |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | SLIWKOWSKI MARK X (US) | 2012-10-04 | — | — | US | claimed |
| US-8163287-B2 | Combination therapy of her expressing tumors | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | claimed |
| EP-2344543-A2 | TREATMENT METHOD | Genentech, Inc. (US) | 2011-07-20 | — | — | EP | claimed |
| JP-2011513427-A | — | — | 2011-04-28 | — | — | JP | claimed |
| EP-2295415-A1 | Quinazoline derivatives | OSI Pharmaceuticals, Inc. (US) | 2011-03-16 | — | — | EP | claimed |
| EP-2257293-A2 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | Genentech, Inc. (US) | 2010-12-08 | — | — | EP | claimed |
| WO-2010045345-A2 | TREATMENT METHOD | GENENTECH, INC. (US) | 2010-04-22 | — | — | WO | claimed |
| US-RE41065-E1 | Alkynl and azido-substituted 4-anilinoquinazolines | PFIZER, INC. (US) | 2009-12-29 | — | — | US | claimed |
| WO-2009111691-A2 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| US-20090226443-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH, INC. (US) | 2009-09-10 | — | — | US | claimed |
| US-20080175797-A1 | PREVENTING AIRWAY MUCUS PRODUCTION BY ADMINISTRATION OF EGF-R ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-07-24 | — | — | US | claimed |
| US-20070020261-A1 | Combination therapy of her expressing tumors | GENENTECH, INC. | 2007-01-25 | — | — | US | claimed |
| EP-0817775-B1 | QUINAZOLINE DERIVATIVES | PFIZER (US) | 2001-09-12 | — | — | EP | claimed |
| EP-1110953-A1 | Quinazoline derivatives | PFIZER INC. (US) | 2001-06-27 | — | — | EP | claimed |
| US-5747498-A | Alkynyl and azido-substituted 4-anilinoquinazolines | PFIZER INC. (US) | 1998-05-05 | — | — | US | claimed |
| EP-0817775-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1998-01-14 | — | — | EP | claimed |
| WO-1996030347-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1996-10-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | KDR 34/4885RET 11/4885KIF5B 3053/4885 |
| US-20070020261-A1 | Combination therapy of her expressing tumors | ERBB2, EGFR, ERBB3 | KDR 34/4885RET 11/4885KIF5B 3053/4885 |
| US-20090226443-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | KDR 33/4885RET 7/4885KIF5B 3211/4885 |
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | KDR 33/4885RET 7/4885KIF5B 3211/4885 |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | KDR 33/4885RET 7/4885KIF5B 3211/4885 |
| US-20080175797-A1 | PREVENTING AIRWAY MUCUS PRODUCTION BY ADMINISTRATION OF EGF-R ANTAGONISTS | EGFR, MUC1, OGFR | KDR 289/4885RET 192/4885KIF5B 1446/4885 |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | KDR 34/4885RET 11/4885KIF5B 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.